Delving into the Latest Updates on Mashhad University of Medical Sciences with Synapse

Comparison of therapeutic effect of nigella sativa and corticosterioid in orabase on oral erosive atrophic lichen planus:A randomized triple blind clinical trial

开始日期2640-06-22

申办/合作机构

Mashhad University of Medical Sciences

IRCT20160710028863N24

/ SuspendedN/AIIT

Effect of a Physicians Communication Skills Training on Health Outcomes and HealthLiteracy Among Hypertensive Patients: a Randomized Controlled Trial

开始日期2634-11-22

申办/合作机构

Mashhad University of Medical Sciences

IRCT20200306046708N1

/ Suspended临床2/3期IIT

Celecoxib added to mood stabilizer for treating acute mania: A randomized, double-blind, placebo-controlled trial

开始日期2633-12-15

申办/合作机构

Mashhad University of Medical Sciences

100 项与 Mashhad University of Medical Sciences 相关的临床结果

登录后查看更多信息

0 项与 Mashhad University of Medical Sciences 相关的专利（医药）

登录后查看更多信息

28,101

项与 Mashhad University of Medical Sciences 相关的文献（医药）

2025-12-31·Hospital Practice

Modified infusion of recombinant tissue plasminogen activator in high-risk pulmonary thromboembolism with high bleeding risk: a case report

Article

作者: Hasin, Mohammad Hussein ; Ahmadi, Mostafa ; Shahri, Bahram ; Baradaran Rahimi, Vafa ; Yadollahi, Asal

High-risk pulmonary thromboembolism (PTE) is a form of venous thromboembolism that refers to severe obstruction of pulmonary vessels, which causes right ventricular failure and hemodynamic instability. High-risk PTE has a high mortality rate unless immediate reperfusion treatment is done. Systemic thrombolysis is recommended for patients with high-risk PTE. The approved regimen for high-risk PTE is the accelerated intravenous administration of recombinant tissue-type plasminogen activator (rtPA) 100 mg over 2 hours. Herein, we present a case of high-risk PTE in a 74-year-old woman with a high risk of bleeding due to a recent pelvic fracture and head trauma who was successfully treated with a slower infusion of 100 mg rtPA over 4 hours. The modified infusion rate of 100 mg rtPA over 4 hours is an effective regimen for thrombolysis in acute high-risk PTE. It might have a lower risk of bleeding complications, which makes it a good option for patients with high bleeding risk.

2025-12-01·Molecular Biology Reports

Retraction Note: Substance P accelerates the progression of human esophageal squamous cell carcinoma via MMP-2, MMP-9, VEGF-A, and VEGFR1 overexpression

作者: Hashemy, Seyed Isaac ; Javid, Hossein ; Afshari, Amir Reza ; Mashkani, Baratali ; Mohammadi, Fariba

2025-12-01·Inflammation Research

Decoy oligonucleotides targeting NF-κB: a promising therapeutic approach for inflammatory diseases

Review

作者: Mahjoubin-Tehran, Maryam ; Butler, Alexandra E ; Rezaei, Samaneh ; Sahebkar, Amirhossein

Nuclear factor-kappa B (NF-κB) transcription factor plays a crucial function in controlling several cellular processes, including the production of inflammatory mediators. The aberrant activation of this transcription factor and its signaling pathway is associated with the pathophysiology of many diseases. Therefore, discovering drugs that target NF-κB is crucial for treating various diseases. Decoy oligonucleotides (decoy ONs) are a pharmacological approach that specifically inhibits NF-κB activation and are used to treat several inflammatory diseases. Decoys that target NF-κB have been shown to enhance radiosensitivity and drug sensitivity in vitro and strongly block IL-6 and IL-8 gene expression induced by TNF-α in experimental cell systems. In vivo, NF-κB decoy reduced atherosclerotic plaque, prevented atopic dermatitis and extended cardiac transplant survival. Decoys have the potential to be used in clinical applications, but they face several challenges. To overcome these limitations, researchers have conducted studies on chemical modifications and delivery techniques. Innovative compounds that target NF-κB, such as NF-κB-decoy-based sensor-containing models, phosphorothioate hairpin-modified oligonucleotides, and peptide nucleic acid (PNA)-based transcription factor decoys, are very attractive. This research aims to explore the use of decoys to combat NF-κB in various disorders.

100 项与 Mashhad University of Medical Sciences 相关的药物交易

登录后查看更多信息

100 项与 Mashhad University of Medical Sciences 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

登录

或

查看完整样例数据

管线布局

2025年05月29日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

临床前

2

5

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

AKBA (Shanghai Jiaotong University) ( NF-κB )	学习障碍更多	临床前
Galbanic acid ( MMP2 x MMP9 )	黑色素瘤更多	临床前
锑酸葡甲胺脂质体(Tehran University of Medical Sciences)	皮肤利什曼病更多	无进展
阿奇霉素脂质体 ( 50S subunit )	皮肤利什曼病更多	无进展
利多卡因/丙胺卡因脂质体(Mashhad University of Medical Sciences) ( SCNA x VDCCs )	疼痛更多	无进展